DETECTION OF MUTATIONS IN EFFLUX PUMP REGULATORY GENES ASSOCIATED WITH ENHANCED DRUG RESISTANCE IN GRAM-NEGATIVE PATHOGENS
Main Article Content
Abstract
Antimicrobial resistance among gram-negative bacterial pathogens represents a growing global health concern, particularly in regions with high antibiotic misuse and limited diagnostic capacity. Efflux pump overexpression is a major mechanism contributing to multidrug resistance (MDR), often driven by mutations in regulatory genes controlling efflux pump activity. This study aimed to detect and characterize mutations in efflux pump regulatory genes associated with enhanced drug resistance in clinically significant gram-negative isolates. A total of 120 clinical specimens were collected from patients admitted to medical, surgical, pediatric, and intensive care units. Bacterial identification was performed using standard cultural and biochemical tests. Antimicrobial susceptibility testing was conducted using the Kirby–Bauer disk diffusion method following CLSI guidelines. MDR isolates were selected for genomic DNA extraction, PCR amplification of regulatory genes (marR, ramR, soxR, mexR, nalC, nalD), agarose gel electrophoresis, and Sanger sequencing. Among the isolates, Escherichia coli (40%) and Klebsiella pneumoniae (26.6%) were the most prevalent, followed by Pseudomonas aeruginosa (18.3%) and Acinetobacter baumannii (15%). High resistance rates were observed to third-generation cephalosporins and fluoroquinolones, while carbapenems remained comparatively more effective. Mutations in marR (63.4%), ramR (51.2%), and soxR (43.9%) were detected in Enterobacteriaceae, whereas mexR (54.5%), nalC (45.4%), and nalD (36.3%) mutations were identified in P. aeruginosa. These genetic alterations correlated strongly with elevated resistance patterns. The findings highlight the significant role of efflux regulatory gene mutations in promoting MDR and emphasize the need for molecular-based diagnostics, antimicrobial stewardship, and evaluation of efflux pump inhibitors to improve therapeutic outcomes.
Downloads
Article Details
Section

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.